Resources Repository
-
Teaching PackPublication, Teaching Resource 2022Teaching Pack: Extended Cost-Effectiveness Analysis
This teaching pack, curated by the Center for Health Decision Science, features videos introducing extended …
This teaching pack, curated by the Center for Health Decision Science, features videos introducing extended cost-effectiveness analysis (ECEA) and detailing how it is conducted, and assembles ECEA publications and teaching materials. In addition to the videos, this teaching pack includes a glossary and tutorial. Videos include: Video 1. Introduction to ECEA (~2 min) Video 2. Quantifying Health Benefits (~4 min) Video 3. Private Expenditures Averted (~3 min) Video 4. Financial Risk Protection (~5 min) Video 5.…
Costing Methods | Health/Medicine | Global | Policy/Regulation | Priority Setting/Ethics | Health Outcomes | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Economics/Finance -
OrganizationWeb Portal 2024Society for Benefit-Cost Analysis
The Society for Benefit-Cost Analysis (SBCA), founded in 2007, works to improve the theory and …
The Society for Benefit-Cost Analysis (SBCA), founded in 2007, works to improve the theory and practice of benefit-cost analysis and support evidence-based policy decisions. It addresses policy areas including public health, transportation, criminal justice, education, energy, environmental quality, homeland security, and poverty. Members include scholars and practitioners from around the world, who work in government, academia, nonprofits and private industry. Its members represent numerous disciplines such as economics, law, engineering, public policy, decision science, and…
Costing Methods | Health/Medicine | Global | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Benefit-Cost Analysis | Social Determinants | Environmental Health | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Education/Labor | Food/Agriculture | Government/Law | Military/Defense | Science/Technology | Critical Thinking/Analysis -
ReportPublication 2017DCP3: Cardiovascular, Respiratory, and Related Disorders
This report from the World Bank is the fifth volume of the Disease Control Priorities, …
This report from the World Bank is the fifth volume of the Disease Control Priorities, Third Edition (DCP3) series. It addresses the disease burden of cardiovascular, respiratory, and related disorders (CVRDs), which account for more than half of global adult deaths, mostly in low- and middle-income countries. While CVRDs are mostly preventable or can be treated to reduce morbidity, such interventions are costly and require greater capacity to detect and treat early. When combined with…
Costing Methods | Health/Medicine | Global | Global Governance | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Social Determinants | Health Systems | Climate/Environment -
ReportPublication 2016DCP3: Mental, Neurological, and Substance Use Disorders
This report from the World Bank is the fourth volume of the Disease Control Priorities, …
This report from the World Bank is the fourth volume of the Disease Control Priorities, Third Edition (DCP3) series. It discusses the prevalence of mental, neurological, and substance use disorders, as well as the associated disability and premature mortality that can accompany them. Despite the high social and economic burden of these diseases on individuals, families, and communities, these disorders have been systematically neglected, especially in low- and middle-income countries, and there has been limited…
Costing Methods | Health/Medicine | Global | Global Governance | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Mental Health | Health Systems | Economics/Finance -
ReportPublication 2015DCP3: Cancer
This report from the World Bank is the third volume of the Disease Control Priorities, …
This report from the World Bank is the third volume of the Disease Control Priorities, Third Edition (DCP3) series. It presents data on the complex patterns of cancer incidence and deaths globally, and offers evidence on effective measures to control cancers. This report identifies settings in which cancer treatment may be ineffective or wasteful, and offers alternative cancer care packages that are cost-effective and better suited to low-resource environments. The Disease Control Priorities Network (DCP)…
Costing Methods | Health/Medicine | Global | Global Governance | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Economics/Finance -
ReportPublication 2015DCP3: Essential Surgery
This report from the World Bank is the first volume of the Disease Control Priorities, …
This report from the World Bank is the first volume of the Disease Control Priorities, Third Edition (DCP3) series. Essential Surgery presents data on the surgical burden of disease, disability, congenital abnormalities, and trauma, as well as the health impact and economic analysis of procedures. This report identifies 44 procedures that address substantial needs, are cost effective, and are feasible to implement in low- and middle-income countries. If made universally available, these 44 procedures could…
Costing Methods | Health/Medicine | Global | Global Governance | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Injuries/Accidents | Health Systems | Clinical Care | Economics/Finance | Science/Technology -
Resource PackPublication, Teaching Resource 2018Resource Pack: Economic Evaluation Guidelines
This resource pack includes guidelines for health economic evaluation - methods designed to identify, measure …
This resource pack includes guidelines for health economic evaluation - methods designed to identify, measure and value the incremental resources used, relative to benefits gained, of alternative interventions or policies - with the goal of improving resource allocation decisions by addressing efficiency in healthcare. The selected examples focus predominantly on the conduct of cost-effectiveness analysis. Over the past three decades, cost-effectiveness analysis has gained increasing attention from decision makers in both resource-rich and resource-poor countries.…
Costing Methods | Health/Medicine | Global | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health Systems | Climate/Environment | Economics/Finance | Government/Law | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
ArticlePublication 2017Costing of National STI Program Implementation, 2016-2021
In 2016 the World Health Assembly adopted the Global Strategy on Sexually Transmitted Infections (STI) …
In 2016 the World Health Assembly adopted the Global Strategy on Sexually Transmitted Infections (STI) 2016–2021 aiming to reduce curable STIs by 90% by 2030. This analysis costed scaling-up priority interventions to achieve coverage targets. Strategy-targeted declines in Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum and Trichomonas vaginalis were applied to WHO-estimated regional burdens at 2012 levels. Case management was costed for the curable STIs, symptomatic Herpes Simplex Virus 2 (HSV-2), and non-STI vaginal syndromes, with incrementally expanding diagnoses. Service…
Costing Methods | Health/Medicine | Global | Infectious Diseases | Evidence Synthesis | Clinical Care | Economics/Finance -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Test Performance | Health/Medicine | Global | Infectious Diseases | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Economics/Finance | North America